t
Ondine Biomedical Inc. announced on November 11, 2024, that the settlement of its Private Placement with a Canadian private investor has been delayed. Consequently, the settlement of the Company's Fundraising, which was scheduled for November 11, 2024, will also be delayed.
| Date | 11 Nov 2024 |
| Time | 07:00:09 |
| Category | Corporate updates |
| ID | 6846L |
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or the "Company")
Update on Private Placement and Placing
Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, announces an update to its Private Placement announced on 24 September 2024 and the Fundraising announced on 1 November 2024.
The settlement of the Private Placement with a Canadian private investor has been delayed due to their unavoidable personal circumstances and will require additional time to complete. In light of this, settlement of the Fundraising scheduled for Nov 11 will also be delayed coinciding with the Private Placement settlement. Further updates will be provided in due course.
-Ends-
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Angelika Vance, Vice President of Corporate Communications |
+001 604 838 2702 |
|
|
|
|
Singer Capital Markets (Nominated Adviser, Joint Broker) |
|
|
Phil Davies, Sam Butcher |
+44 (0)20 7496 3000 |
|
|
|
|
RBC Capital Markets (Joint Broker) |
|
|
Rupert Walford, Kathryn Deegan |
+44 (0)20 7653 4000 |
|
|
|
|
Vane Percy & Roberts (Media Contact for Ondine Biomedial) |
+44 (0)77 1000 5910 |
|
Simon Vane Percy, Amanda Bernard |
|
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.